Nutriband Inc (NTRB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$5.80-4.92%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Nutriband is launching a new fentanyl patch with peak sales potential of $80M to $200M. Operating losses have improved from -$3.88M to -$1.25M recently. The company secured a $5M credit line to support growth. These show progress despite current losses.
Revenue is still very low and analysts expect a 27% decline next year. The company remains unprofitable with negative cash flow. The recent sharp stock selloff reflects these risks.
The stock trades about 51% above our fair value near $2 despite expected revenue decline of -27%. The market is overly optimistic on growth and turnaround prospects.
Breaks if: credit line is reduced or withdrawn before 2027-Q1
Manage liquidity and capital structure prudently through a $5 million credit line facility with favorable terms.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
NTRB represents a speculative growth investment, focusing on the commercialization of its fentanyl transdermal system. The current thesis is intact, supported by recent FDA approval, but the company remains loss-making with high risk factors.
The market currently prices NTRB at a premium compared to peers, reflecting an expectations gap. This suggests that investors may be anticipating future successes that have not yet materialized.
Management is making progress in reducing net losses, though the company continues to face liquidity challenges. Recent financial performance has been neutral, with operating income showing some improvement.
The thesis hinges on the company's ability to successfully commercialize its fentanyl transdermal system and manage financial discipline. Additionally, broader sector momentum and guidance from key industry players will be critical.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. NTRB's recent financial performance fell from the robust 62nd to the 26th percentile of its sector. This change indicates a decline in the company's standing among its peers. The market has reacted only modestly since then, showing no clear direction.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of last 2 quarters. Operating income remains negative, -$1.25M in 2027-Q1 and -$0.89M in 2027-Q2, with net losses continuing. The credit line provides stable financing without equity dilution. Management maintains financial discipline but losses persist, indicating mixed progress.
“Entered into an amended three-year $5,000,000 credit line facility with 7% interest and no stock conversion.”
“The credit line provides the Company with financing through June 2029 without conversion to common stock.”
Breaks if: operating losses worsen beyond -$1.25M by 2027-Q1
Focus on reducing operating losses and net income deficits through operational improvements and cost management.
Stated in 5 of last 5 quarters. Operating income improved significantly from -$3.88M in 2026-Q3 to -$0.89M in 2027-Q2; net losses also narrowed from -$3.87M to -$0.88M. Management has consistently emphasized reducing losses and the financials show delivering progress on this priority.
“Operating income was -$890,637 and net income was -$880,561.”
“Operating income was -$1,254,351 and net income was -$1,241,956.”
“Operating income was -$1,020,915 and net income was -$968,059.”
“Operating income was -$3,880,336 and net income was -$3,872,367.”
“Operating income was -$2,003,213 and net income was -$2,000,337.”
Breaks if: annual US sales fail to grow toward $80M by 2026-Q1
Advance development and regulatory approval of the AVERSA™ abuse deterrent fentanyl patch targeting peak US sales of $80M to $200M annually.
Stated as a priority in 3 of last 3 quarters. Revenue declined from $622K in 2026-Q2 to $438K in 2027-Q2, reflecting early commercial stage. Management projects peak US sales of $80M to $200M annually for the fentanyl patch. The trajectory shows limited revenue progress so far but consistent focus on commercialization.
“Nutriband’s abuse deterrent fentanyl transdermal system has the potential to reach peak annual US sales of $80 million to $200 million.”
“AVERSA™ FENTANYL has the potential to reach peak annual US sales of $80 million to $200 million.”
“Nutriband has selected the commercial worldwide brand name for its abuse deterrent fentanyl transdermal system and will submit to the FDA for approval.”
Over the next 1 to 3 years, NTRB's performance will depend on its execution and external market conditions. Not investment advice.